Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis

BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death

(2011) Mark Wade et al.   CELL CYCLE

The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer

(2010) Marianne Farnebo et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53

(2009) Tom Van Maerken et al.   JNCI-Journal of the National Cancer Institute

MDM2-Dependent Inhibition of p53 Is Required for Epstein-Barr Virus B-Cell Growth Transformation and Infected-Cell Survival

(2009) E. Forte et al.   JOURNAL OF VIROLOGY

Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein–Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells

(2009) B Renouf et al.   LEUKEMIA

Small-molecule inhibitors of MDM2 as new anticancer therapeutics

(2009) Michael P. Dickens et al.   SEMINARS IN CANCER BIOLOGY

The genetics of the p53 pathway, apoptosis and cancer therapy

(2008) Alexei Vazquez et al.   NATURE REVIEWS DRUG DISCOVERY

How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

(2008) Jerry E. Chipuk et al.   TRENDS IN CELL BIOLOGY

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY